Please login to the form below

Daniel O'Day

This page shows the latest Daniel O'Day news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” said Daniel O’Day, chairman and chief executive officer of Gilead.

Latest news

Gilead makes a play for novel cancer drug with Tizona deal

Tizona is pursuing first-in-class cancer immunotherapies that could make an important difference in oncology by helping patients who don’t respond to current checkpoint inhibitors,” said Daniel O’Day,
Gilead and Arcus complete closing of ten-year immunotherapy partnership

Gilead is committed to accessing the world’s best innovation in immuno-oncology and our agreement with Arcus further demonstrates that commitment,” said Daniel O’Day, chairman and chief executive officer, ... Gilead has been expanding into
UPDATED: Gilead drops remdesivir’s orphan drug designation

Responding to the designation, consumer group Public Citizen said in a letter to Gilead CEO Daniel O’Day: “This is an unconscionable abuse of a programme designed to incentivise research and
Gilead swoops on Forty Seven with $4.9bn all-cash deal

The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel ... Magrolimab complements our existing work in haematology, adding a non-cell
Gilead promotes Andrew Dickinson to CFO, increased M&A expected

With the transformation of Gilead’s pipeline CEO Daniel O’Day’s top priority, Dickinson will be expected to be taking the helm of many future deals and collaborations. ... Daniel O'Day. “Over the past months, one of my key priorities has been

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

As COVID-19 takes over the world, biopharma fights back

A number of clinical trials evaluating remdesivir’s efficacy in COVID-19 are currently underway in China and the US, with Gilead CEO Daniel O’Day commenting that “initial data” is ... have activity for,” added O’Day.
20 for 2020 – Five pharma leaders to watch in 2020

The pipeline-building deal is the largest under new Gilead chief executive Daniel O’Day, who took the helm of Gilead in March 2019, and includes a massive $3.95bn upfront,
The rise of real-world evidence

Having been stung by drugs that shine in RCTs but under deliver in day-to-day practice, these stakeholders want to know what effect therapies will have on people in the ... The takeover was driven by a belief that “regulatory-grade real-world evidence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Ex-Roche CMO Sandra Horning joins Gilead’s board of directors

We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day (pictured right), chairman and chief executive officer of Gilead Sciences.
AstraZeneca hires Roche’s Pascal Soriot as CEO

At Roche, Daniel O'Day, currently chief operating officer Roche Diagnostics has been appointed as Soriot's replacement as chief operating officer of Roche Pharma effective September 1, 2012. ... O'Day will be succeeded by Roland Diggelmann, currently

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...